Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
Flexible Endoscopic Surgery Robot Market Size & Share 2026-2035
Report ID: GMI15095
|
Published Date: September 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Explore Our Licensing Options:
Flexible Endoscopic Surgery Robot Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Flexible Endoscopic Surgery Robot Market Size
The flexible endoscopic surgery robot market was valued at USD 1.08 billion in 2025, is expected to reach USD 1.21 billion in 2026, and is projected to grow at a 15.3% CAGR from 2026 to 2035 to reach USD 4.39 billion by 2035.
Flexible Endoscopic Surgery Robot Market Key Takeaways
Market Leader: Intuitive Surgical (Ion) led with over 35% market share in 2025.
Leading Players: Top 5 players in this market include J&J/Auris Health (Monarch), Noah Medical (Galaxy), Langhe Medical, EndoMaster, Intuitive Surgical (Ion), which collectively held a market share of 46% in 2025.
The Flexible Endoscopic Surgery Robot Market is evolving from a niche capital-equipment category into an installed-base business shaped by procedure utilization. Robotic navigation expands access to peripheral airways, upper-tract lesions, and difficult gastrointestinal anatomy, while recurring instruments, accessories, and service contracts increase revenue density after platform placement. The result is a market where clinical throughput and ecosystem retention matter as much as initial system sales.
GMI Analyst View
Based on our proprietary analysis combining platform-operator financial disclosures and clinical utilization data, the global flexible endoscopic surgery robot market reached USD 974.3 million in the year preceding the base year. In our view, this establishes a credible foundation for continued installed-base utilization, particularly where robotic navigation improves access to anatomically challenging targets and supports recurring procedural revenue.
Flexible Endoscopic Surgery Robot Market Trends, Growth Drivers & GMI Forecast Outlook
Clinical demand is being shaped by earlier lesion detection, greater need for precision access, and the migration of minimally invasive procedures toward more distributed care settings. Adoption remains uneven because equipment economics, reimbursement pathways, and regulatory synchronization determine whether clinical interest translates into platform placement and sustained procedural use.
Key Drivers
*Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.*
Lung cancer creates an especially direct demand pathway for robotic bronchoscopy because suspicious peripheral nodules often require tissue access beyond the practical reach of conventional flexible scopes. An estimated 2.6 million new lung cancer cases were diagnosed worldwide in 2024, and lung cancer accounted for approximately 19% of cancer-related mortality [1]International Agency for Research on Cancer. “Global Cancer Statistics 2024: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 34 Cancers in 186 Countries.” iarc.who.int. Screening-led nodule identification is therefore increasing the clinical importance of accurate, minimally invasive biopsy workflows.
For providers, the economic significance lies not only in a system placement but also in the repeat use of procedure-specific instruments and accessories. Ion's reported procedure growth in FY2025 illustrates how utilization can build after installations are established [3]GlobeNewswire. “Intuitive Announces Preliminary Fourth Quarter and Full Year 2025 Results.” globenewswire.com. This favors vendors that can pair navigational precision with physician training, workflow integration, and dependable recurring-supply logistics.
The ambulatory opportunity is structurally distinct from the traditional academic-hospital adoption model. Flexible robotic configurations that reduce room turnover friction, limit reprocessing burden, and fit outpatient cost structures can widen the capital-acquisition base. The channel's progress will depend on whether manufacturers deliver credible economics without compromising clinical capability in procedures that have historically required hospital-grade infrastructure.
Software-enabled navigation is also changing the commercial basis of competition. AI-assisted registration, real-time imaging integration, and scope-tip orientation can reduce the operational uncertainty associated with peripheral access. As these capabilities are introduced through iterative platform updates, vendors may reinforce account retention without requiring institutions to replace their installed capital equipment.
Key Restraints
*Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.*
Capital intensity limits the buyer universe and heightens the importance of institutional prioritization. Systems must compete with other surgical, imaging, and digital-health investments for constrained capital budgets, while purchasers also evaluate service commitments, consumable spending, staff training, and room-integration requirements. This creates a material adoption gap between well-resourced health systems and community providers.
Hospital-led procurement can also make placement revenue lumpy. Multistakeholder review, group-purchasing arrangements, and budget cycles may delay an otherwise clinically attractive purchase. In this setting, installed-base utilization becomes a key buffer: procedure growth within existing accounts can sustain demand for recurring products even when new system placements are deferred.
Regulatory fragmentation adds another constraint for software-defined platforms. Manufacturers must align clinical, technical, and regulatory evidence across jurisdictions before comparable navigation capabilities can be deployed broadly. The resulting version differences can slow physician standardization and postpone the efficiency gains that make flexible robotic procedures more scalable outside specialized referral centers.
GMI Analyst View
We view the forecast as a staged diffusion process rather than a uniform global rollout. Established bronchoscopy programs provide the initial utilization base, while broader expansion depends on reimbursement reliability, capital models suited to outpatient care, and the ability of navigation software to reduce dependence on highly specialized operators. The principal downside risk is not clinical relevance; it is the pace at which procurement and payment systems accommodate the technology.
Flexible Endoscopic Surgery Robot Market Segment Analysis
By Category
The therapeutic category generated USD 630.5 million in 2025 and is projected to account for 62.0% of the market by 2035. Therapeutic procedures capture the market's strongest revenue logic because robotic guidance supports interventions rather than visualization alone. Tissue sampling, ablation, stone management, endoscopic dissection, and other endoluminal procedures can create both a compelling clinical-use case and sustained demand for procedure-specific instruments. The category's trajectory reflects the expanding use of robotic platforms where dexterity, reach, and stability affect treatment delivery.
The diagnostic category represented 42.0% of the market in 2025 and is projected to reach USD 1.66 billion by 2035. Diagnostic platforms retain an important role in screening and visualization, particularly where robotic actuation may improve patient tolerance or scope control. Global colorectal cancer incidence continues to support the underlying need for more effective screening pathways, with approximately 1.9 million new cases and more than 900,000 deaths reported worldwide in 2022 [6]World Health Organization. “Colorectal Cancer.” who.int. However, the category faces a strategic challenge: as formerly diagnostic platforms gain interventional functionality, value may migrate toward therapeutic use cases.
By Application
The Flexible Endoscopic Surgery Robot Market's urology application generated USD 445.7 million in 2025 and is projected to represent 43.0% of the market by 2035. Urology benefits from predictable treatment demand, specialist referral pathways, and procedure settings where greater control over flexible instrumentation can be clinically meaningful. Robotic ureteroscopy is particularly relevant where access, visualization, and maneuverability influence stone-management workflows and upper-tract interventions. Its commercial potential is broadened by the presence of platform activity across multiple geographies rather than a single-country installed base.
Respiratory applications represented 32.0% of the market in 2025 and are projected to reach USD 1.18 billion by 2035. Respiratory robotics remain closely tied to the need for earlier, more accurate evaluation of peripheral pulmonary lesions. Rising lung cancer burden heightens the importance of reliable access to suspicious nodules, especially as screening identifies more patients requiring diagnostic clarification [1]International Agency for Research on Cancer. “Global Cancer Statistics 2024: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 34 Cancers in 186 Countries.” iarc.who.int. The segment's outlook rests on continued clinical validation, utilization within existing accounts, and the extension of robotic bronchoscopy capabilities into additional care settings.
Gastrointestinal applications represented 22.0% of the market in 2025 and are projected to grow at a 17.0% CAGR (2026-2035). Gastrointestinal robotics are advancing across endoscopic submucosal dissection, screening-oriented colonoscopy, and other complex endoluminal procedures. The clinical opportunity is substantial, but commercialization remains dependent on evidence that robotic assistance improves procedural precision, efficiency, or access relative to established endoscopic practice. The segment's development will be influenced by reimbursement progress and the ability of vendors to fit high-volume endoscopy workflows.
Other applications remain a selective opportunity spanning ENT, pancreatobiliary, reproductive, and related anatomical-access procedures. Their growth depends on narrow indication development, clinician advocacy, and whether vendors can justify dedicated workflow investment for lower-volume use cases.
By End Use
Hospitals & Clinics generated USD 804.4 million in 2025 and are projected to account for 65.0% of the market by 2035. Hospitals and clinics remain the core adoption setting because they can absorb system integration requirements, credential multidisciplinary teams, and consolidate procedure volume across specialties. Their continued importance does not imply a static model; health systems are increasingly evaluating utilization, room efficiency, and recurring-cost discipline alongside the clinical differentiation of each platform.
Ambulatory Surgical Centers generated USD 228.3 million in 2025 and are projected to represent 30.0% of the market by 2035. ASC adoption reflects the potential for flexible robotic procedures to move closer to outpatient care when reimbursement, staffing, and device configuration align. The commercial opportunity is strongest for platforms that can deliver predictable setup, compatible disposable components, and a cost profile appropriate for high-throughput facilities. Success in this channel could reshape vendor sales models from institution-led capital placements toward more distributed procedural networks.
Other end-use settings, including research institutions and dedicated endoscopy centers, provide a smaller but strategically useful base for clinical evaluation, physician training, and targeted specialty programs. Their relevance lies less in immediate volume than in their contribution to evidence generation and early workflow refinement.
GMI Analyst View
We see the segment mix as a contest between clinical maturity and future addressable volume. Bronchoscopy established the commercial template for flexible robotics, urology offers repeatable specialist-driven demand, and gastrointestinal applications present the largest unresolved opportunity. The decisive issue will be whether vendors can move robotic endoscopy from concentrated centers of excellence into routine, high-volume procedural settings without losing economic discipline.
Flexible Endoscopic Surgery Robot Market Regional Analysis
North America Flexible Endoscopic Surgery Robot Market Analysis
The Flexible Endoscopic Surgery Robot Market in North America generated USD 674.0 million in 2025 and is projected to represent 47.0% of global revenue by 2035. North America benefits from early clinical adoption, established robotic surgery relationships, and comparatively developed reimbursement mechanisms for relevant procedures. The region's installed base provides a foundation for recurring revenue growth, while expanding outpatient use can create an additional deployment pathway. Its lower future share reflects global market broadening rather than a loss of strategic importance.
United States
The Flexible Endoscopic Surgery Robot Market in the United States generated USD 609.8 million in 2025 and is projected to grow at an 11.9% CAGR (2026-2035). The United States remains the pivotal commercial market for robotic bronchoscopy because of its concentration of early adopters, established provider networks, and iterative regulatory pathway for platform upgrades. Continued demand will depend on providers' ability to translate clinical confidence into utilization across a wider range of pulmonary and urological workflows.
Europe Flexible Endoscopic Surgery Robot Market Analysis
The Flexible Endoscopic Surgery Robot Market in Europe represented 17.0% of global revenue in 2025 and is projected to reach USD 835.0 million by 2035. European adoption is supported by a strong endoscopy research base and meaningful activity in flexible ureteroscopy and gastrointestinal innovation. The region remains heterogeneous, however, because funding and reimbursement decisions are made across national health systems. This favors vendors that can demonstrate procedure-specific value and support local evidence-generation requirements.
Germany
The Flexible Endoscopic Surgery Robot Market in Germany represented 5.2% of global revenue in 2025 and is projected to reach USD 235.0 million by 2035. Germany's position reflects its role as a major European adopter of advanced medical technology and its concentration of university hospitals capable of evaluating complex flexible robotic procedures. Growth will be linked to how effectively robotic ureteroscopy and gastrointestinal systems integrate with established endoscopy programs and hospital purchasing priorities.
United Kingdom
The Flexible Endoscopic Surgery Robot Market in the United Kingdom represented 4.0% of global revenue in 2025 and is projected to reach USD 175.0 million by 2035. The United Kingdom's adoption pattern is likely to remain concentrated in specialized thoracic and endoscopy referral centers, where clinician expertise and pathway coordination can support complex robotic procedures. Screening initiatives and the need for efficient diagnostic pathways may reinforce interest, but broader diffusion will require clear value within NHS procurement and service-delivery structures.
Asia Pacific Flexible Endoscopic Surgery Robot Market Analysis
The Flexible Endoscopic Surgery Robot Market in Asia Pacific generated USD 163.1 million in 2025 and is projected to grow at a 22.0% CAGR (2026-2035). Asia Pacific combines substantial disease burden, deep endoscopy expertise, and growing domestic medical-device capability. China's platform development and procurement momentum, alongside Japan's established gastrointestinal endoscopy infrastructure, create multiple routes to expansion. The region's growth potential is especially significant where local manufacturers can adapt platform economics to high-volume hospital workflows.
China
The Flexible Endoscopic Surgery Robot Market in China represented 9.0% of global revenue in 2025 and is projected to reach USD 780.0 million by 2035. China's outlook is shaped by domestic platform commercialization, large hospital systems, and substantial demand for earlier intervention in pulmonary and gastrointestinal disease. Local suppliers could become increasingly consequential if they establish clinical credibility while offering systems aligned with national procurement priorities and regional cost structures.
Japan
The Flexible Endoscopic Surgery Robot Market in Japan generated USD 54.4 million in 2025 and is projected to grow at a 12.6% CAGR (2026-2035). Japan's long-standing expertise in conventional flexible endoscopy gives it a strong clinical base for gastrointestinal robotic applications. Adoption is likely to be evidence-led, with providers placing particular weight on procedural quality, equivalence, and the practical contribution of robotics within mature endoscopy pathways.
Latin America Flexible Endoscopic Surgery Robot Market Analysis
The Flexible Endoscopic Surgery Robot Market in Latin America represented 3.0% of global revenue in 2025 and is projected to reach USD 198.0 million by 2035. Latin American demand remains concentrated in private hospital networks and major urban centers, where advanced-procedure infrastructure is most available. The central constraint is not clinical need but the limited availability of consistent reimbursement and capital funding. Expansion will depend on whether vendors can establish viable financing, training, and service models outside premium private-provider settings.
Middle East & Africa Flexible Endoscopic Surgery Robot Market Analysis
The Flexible Endoscopic Surgery Robot Market in Middle East & Africa generated USD 32.5 million in 2025 and is projected to grow at a 20.4% CAGR (2026-2035). Investment in surgical and diagnostic capacity across selected Gulf markets provides an entry point for flexible robotic platforms, particularly within tertiary hospitals pursuing advanced-care differentiation. Adoption outside those hubs will remain constrained by infrastructure, reimbursement, and specialist availability, making the region a targeted rather than broad-based commercial opportunity.
GMI Analyst View
We view regional development as a progression from installed-base utilization toward price-sensitive expansion. North America remains the reference market for commercial execution, Europe offers selective but clinically sophisticated adoption, and Asia Pacific carries the greatest potential to reshape platform economics. The long-term competitive question is whether regional manufacturing and local procurement models can broaden access while preserving the service and consumable economics that support vendor investment.
Flexible Endoscopic Surgery Robot Market Share & Competitive Landscape
The Flexible Endoscopic Surgery Robot Market share landscape is led by large MedTech platforms with the capital resources, clinical evidence capabilities, and service infrastructure needed to commercialize complex endoluminal systems. Competition is centered on navigational accuracy, procedure-specific workflow design, installed-base utilization, regulatory iteration, and the ability to secure recurring instrument and service revenue after capital placement.
Intuitive Surgical
Intuitive Surgical held an estimated 35.0% global market share in 2025.
Ion provides Intuitive Surgical with a leading position in robotic bronchoscopy, supported by the company's broad hospital relationships and experience operating a high-value capital-and-consumables business model. Its strategic advantage lies in connecting procedural evidence, physician training, and recurring instrument demand into a cohesive account-level offering. Maintaining leadership will require continued utilization gains and a defensible response to competing navigation capabilities.
Johnson & Johnson
Johnson & Johnson held an estimated 17.0% global market share in 2025.
MONARCH is the principal competitive alternative to Ion in robotically assisted bronchoscopy and is differentiated by its emphasis on software-enabled navigation. The platform's ability to incorporate upgraded imaging and guidance functionality through iterative clearances can strengthen institutional retention and give the company a pathway to compete on more than hardware design. Its success will depend on converting technical differentiation into durable clinical workflow preference.
Medrobotics
Medrobotics held an estimated 1.0% global market share in 2025.
Medrobotics remains a specialized participant whose commercial trajectory illustrates the financing demands of flexible surgical robotics. Its future relevance depends on product revitalization, focused indication development, and the ability to compete in niches where flexible access offers a clear advantage over conventional alternatives.
Endo Tools Therapeutics
Endo Tools Therapeutics is positioned around flexible triangulation for bariatric and foregut procedures. Its narrower focus can support differentiated clinical positioning, although broader market expansion will depend on the pace of adoption for advanced therapeutic endoscopy and the company's ability to scale beyond its European base.
Endotics
Endotics is developing self-propelled robotic colonoscopy systems for European clinical settings. Its opportunity is linked to screening pathways, patient-comfort considerations, and evidence that robotic colonoscopy can provide differentiated value in anatomically challenging cases.
GI View
GI View markets a robotic self-propelling colonoscopy platform with limited commercial scale. The company's competitive prospects depend on establishing procedural efficiency and clinical differentiation relative to conventional colonoscopy within a market where provider familiarity and reimbursement remain decisive.
Recent Industry Developments
Johnson & Johnson MedTech - MONARCH QUEST 3 FDA Clearance
Johnson & Johnson MedTech received U.S. FDA 510(k) clearance for MONARCH QUEST 3 in August 2026 [5]Johnson & Johnson. “Johnson & Johnson Announces MONARCH QUEST 3, Advancing the Latest in Robotically Assisted Bronchoscopy.” jnj.com. The update added AI-powered pulmonary nodule segmentation, enhanced registration stability, a 3D Compass orientation overlay, and expanded compatibility with cone-beam CT imaging systems. The development underscores the growing importance of iterative software releases as a means of strengthening platform capability and institutional engagement in robotic bronchoscopy.
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →